SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

A strong quarterly earnings report and ambitious AI-compute expansion outlook are fueling bullish interest, while traders debate the spending plans, valuation, and potential Tesla merger. The large share unlock and profit-taking are tempering enthusiasm, with some traders viewing the added supply as a risk to the post-earnings rally.

Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company was founded on June 3, 2024 is headquartered in New York, NY.

Skydance Corp. - Ordinary Shares - Class B

The distribution and separate trading of long-dated warrants has driven sharp price swings and confusion over whether the share-price drop was mainly a mechanical adjustment or a loss in value. Some holders say the shares and warrants should be considered together, while skeptics point to dilution and the heavy debt from the Warner Bros. Discovery deal.

Strive, Inc. engages in the provision of an asset management Bitcoin treasury. It is focused on maximizing value for shareholders, accumulating bitcoin and outperforming bitcoin over the long run. The company was founded by Arshia Sarkhani, Jackson Fairbanks, Arman Sarkhani, and Kyle Fairbanks on March 9, 2022 and is headquartered in Dallas, TX.

Strive Inc. - Ordinary Shares - Class A

Strive Inc.

Strives expanded Bitcoin treasury and the closing/listing of its SATS preferred offering are fueling attention, with bulls viewing the proceeds as capital for further Bitcoin purchases. The rally is drawing enthusiasm, while skeptics warn that the high dividend burden and potential share issuance could weigh on common shareholders.

Lam Research Corp. engages in the design, manufacture, marketing, refurbishment, and provision of semiconductor processing equipment used in the fabrication of integrated circuits. It operates through the following geographical segments: United States, China, Europe, Japan, Korea, Southeast Asia, and Taiwan. The company was founded by David K. Lam in 1980 and is headquartered in Fremont, CA.

Lam Research Corp.

Lam Research is drawing attention ahead of its earnings report, with traders debating whether the recent selloff reflects pre-report profit-taking or a possible leak; claims of leaked results remain speculation. Some see the pullback as a buying opportunity, while others are wary of further downside and the options-implied move.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas quarterly earnings are the dominant focus, with traders watching AI spending guidance and whether the Muse rollout can show traction and justify the investment. Views are split: bulls expect AI momentum to support growth, while bears worry that rising capex, weaker cash flow and a New Mexico privacy ruling could weigh on the stock.

Six Flags Entertainment Corp. engages in operating amusement parks in North America. It operates amusement parks, water parks, and resorts. The company is headquartered in Charlotte, NC.

Six Flags Entertainment Corp.

Six Flags Entertainment Corp

Six Flags is under pressure after Mizuho cut its outlook, amid continued fallout from a fatal roller-coaster accident, precautionary ride closures, and fresh safety concerns. Bears worry about reputational damage, legal exposure, and the companys debt, while some traders view the selloff as overdone and point to short-squeeze potential.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD is drawing attention after its latest earnings report showed a revenue decline but improved profitability and cash flow, yet shares sold off sharply. Traders are debating whether the drop is an overreaction to otherwise solid results or reflects weak Chinese consumer demand and persistent pressure on the companys growth.

Icahn Enterprises LP is a holding company. It operates through the following segments: Investment, Automotive, Energy, Food Packaging, Real Estate, Home Fashion, Pharma, and Holding Company. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group, LLC. The Energy segment refers to petroleum refining and marketing businesses. The Food Packaging segment involves the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Real Estate segment offers rental real estate, property development, and resort activities. The Home Fashion segment deals with manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operate through Vivus, Inc., a specialized pharmaceutical company. The Holding Company segment manages acquisition and investment in operating businesses. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

IEP is drawing attention amid a steep selloff and concerns about potential hedging losses, debt maturities, and whether its distribution is sustainable ahead of earnings. Holders are frustrated by Icahns limited communication, while some bullish traders point to IEPs CVR Energy stake and speculate about a short squeeze or a rebound.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Uniteds quarterly earnings miss and sharply lower fourth-quarter profit guidance, driven by elevated fuel costs, are prompting debate as shares rally despite the weak outlook. Traders are weighing margin pressure against record revenue, resilient travel demand and expectations for continued revenue growth.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor is drawing attention ahead of an FDA decision on deramiocel for Duchenne muscular dystrophy, particularly the narrowed application focused on upper-limb function and the HOPE-3 data. Traders are divided: some see a path to approval, while others cite the prior advisory committee vote and disputed statistical analyses as risks; the uncertainty is fueling volatile trading and speculation about short-selling pressure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025 TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025PR NewswireTAMPA, Fla., Oct. 13, 2026Patent extends coverage to include bispecific/multi-specific...

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) TechnologyPR NewswireTAMPA, Fla., Oct...

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers

TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the...

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference

TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference TuHURA Biosciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire TAMPA, Fla., Sept. 8, 2026 TAMPA, Fla., Sept. 8, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc...

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update PR Newswire TAMPA, Fla., Aug. 14, 2026 TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences...

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference

TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference PR Newswire TAMPA, Fla., July 22, 2026 TAMPA, Fla., July 22, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or...

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers

TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood Related Cancers TuHURA Biosciences Files Investigational New Drug Application for Evaluation of the TBS-2025 VISTA Inhibiting...

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR...

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference PR...

TuHURA Biosciences (NASDAQ:HURA) Earns Outperform Rating from Analysts at Citizens Jmp

Citizens Jmp initiated coverage on shares of TuHURA Biosciences in a report on Monday. They issued an "outperform" rating and a $9.00 price objective for the company...

This account has been verified as an official HURA representative.

Verified Account

Tu HURA Responder

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. Its lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded by Michael Lawman, Patricia Lawman and James A. Bianco on May 4, 2023 and is headquartered in Tampa, FL.

TuHURA Biosciences Inc.

This Small-Cap Biotech Stock Has Sparked A 7,000% Surge In Retail Chatter — Here’s Why

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Orphan drug status adds regulatory incentives and boosts visibility for IFx-2.0.</li><li>Early trial data showed the treatment was safe with signs of benefit.</li><li>The news reignited retail interest after recent analyst resets, pipeline updates, and a financing that extended the company’s development runway.</li></ul>Shares of TuHURA Biosciences drew intense retail chatter on Tuesday after the company said the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its melanoma therapy.<h2 class="st-heading-2">FDA Orphan Drug Designation For IFx-2.0</h2>TuHURA said the FDA’s Office of Orphan Products Development granted Orphan Drug Designation to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma. The designation is based on data from a previously completed Phase 1 study, which showed IFx-2.0 was safe with no serious dose-limiting toxicities.The study also&nbsp;found that some patients whose cancers had stopped responding to prior immunotherapy later responded when treated with standard immune checkpoint inhibitors.Orphan Drug Designation provides seven years of market exclusivity upon approval, along with tax credits for certain research costs, access to FDA grants, better regulatory guidance, and a waiver of New Drug Application user fees.TuHURA said its near-term focus remains on completing enrollment in its Phase 3 trial of IFx-2.0 in combination with Keytruda for first-line treatment of advanced or metastatic Merkel cell carcinoma.<h2 class="st-heading-2">Portfolio Updates</h2>In December, TuHURA announced the release of contingent value rights tied to legacy Kintara Therapeutics assets after a REM-001 clinical trial in metastatic cutaneous breast cancer met its primary endpoint, demonstrating safety and signs of clinical efficacy. The milestone triggered the release of more than 1.5 million TuHURA shares to former Kintara stockholders under the CVR agreement.Additionally, the company highlighted early research and patient-related data supporting its experimental antibody, TBS-2025, which it said showed survival benefits, particularly when used alongside standard chemotherapy or other targeted treatments.TuHURA also said a recently completed financing, which raised $15.6 million in gross proceeds, is expected to fund key milestones across its three development programs, including IFx-2.0, TBS-2025, and earlier-stage immune-modulating platforms.Last month,&nbsp; H.C. Wainwright lowered its price target on TuHURA to $10 from $12 while maintaining a ‘Buy’ rating. The brokerage said at the time that upcoming value inflection points, combined with a recent decline in the stock, created what he described as an attractive entry point for investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TuHURA was ‘bullish’ amid a 7,300% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hura_ss_png_6d663076c8.webp" alt="hura ss.png" width="971" height="139"><figcaption>HURA sentiment and message volume as of February 3 | Source: Stocktwits</figcaption></figure>One user called the fall in stock price a “real loading zone.”<stembedurl>https://stocktwits.com/Gotsomescrewsmissing/message/643709473</stembedurl>Another trader suggested the company’s latest capital raise could wrap up much earlier than expected.<stembedurl>https://stocktwits.com/Gotsomescrewsmissing/message/643695662</stembedurl><a href="https://stocktwits.com/symbol/HURA">TuHURA’s stock</a> has declined 90% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

TuHURA’s stock has declined 90% over the past 12 months. (Representative Image: Getty Images)

Hura Stock - The company is focused on completing enrollment in its Phase 3 IFx-2.0 study with Keytruda for advanced Merkel cell carcinoma.

HURA Stock Sparks 7,000% Surge In Retail Chatter After FDA Orphan Drug Win For Melanoma Therapy

The company is focused on completing enrollment in its Phase 3 IFx-2.0 study with Keytruda for advanced Merkel cell carcinoma.

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

Meta ($META) reports earnings after the close today. What do you expect?

Stocktwits

) reports earnings after the close today. What do you expect?

Current Price	$2.02
Prev Close	$1.76
Open	$1.83
Dividend Yield	0.00%
50-Day Moving Average	$2.06
Beta	0.88
Avg. Volume	205,996.08
PE Ratio	-3.30

52-Week High	$3.43
52-Week Low	$0.41
Market Capitalization	$112.16M
EPS (Annual)	-$0.6272
Price to Book	6.15
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

HURA Fundamentals